Musatti L - Search Results

1

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

Robert E, Musatti L, Piscitelli G, Ferrari CI. Robert E, et al. Among authors: musatti l. Reprod Toxicol. 1996 Jul-Aug;10(4):333-7. doi: 10.1016/0890-6238(96)00063-9. Reprod Toxicol. 1996. PMID: 8829257

2

Treatment of macroprolactinoma with cabergoline: a study of 85 patients.

Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF. Ferrari CI, et al. Among authors: musatti l. Clin Endocrinol (Oxf). 1997 Apr;46(4):409-13. doi: 10.1046/j.1365-2265.1997.1300952.x. Clin Endocrinol (Oxf). 1997. PMID: 9196602

3

Pharmacokinetics of acipimox and of its N-deoxy metabolite following single and repeated oral administration to healthy volunteers.

Efthymiopoulos C, Strolin Benedetti M, Poggesi I, Ruff F, Basileo G, Musatti L. Efthymiopoulos C, et al. Among authors: musatti l. Therapie. 1993 Jan-Feb;48(1):23-6. Therapie. 1993. PMID: 8356541

4

Acipimox-induced facial skin flush: frequency, thermographic evaluation and relationship to plasma acipimox level.

Pontiroli AE, Fattor B, Pozza G, Pianezzola E, Strolin Benedetti M, Musatti L. Pontiroli AE, et al. Among authors: musatti l. Eur J Clin Pharmacol. 1992;43(2):145-8. doi: 10.1007/BF01740661. Eur J Clin Pharmacol. 1992. PMID: 1425871 Clinical Trial.

5

Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

Musatti L, Maggi E, Moro E, Valzelli G, Tamassia V. Musatti L, et al. J Int Med Res. 1981;9(5):381-6. doi: 10.1177/030006058100900515. J Int Med Res. 1981. PMID: 7028536 Clinical Trial.

6

Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.

Crepaldi G, Avogaro P, Descovich GC, Di Perri T, Postiglione A, Sirtori CR, Strano A, Ventura S, Musatti L. Crepaldi G, et al. Among authors: musatti l. Atherosclerosis. 1988 Mar;70(1-2):115-21. doi: 10.1016/0021-9150(88)90105-0. Atherosclerosis. 1988. PMID: 3281679 Clinical Trial.

7

Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism.

Edlund A, Musatti L, Wennmalm A. Edlund A, et al. Among authors: musatti l. Eur J Clin Pharmacol. 1990;39(1):37-41. doi: 10.1007/BF02657054. Eur J Clin Pharmacol. 1990. PMID: 2125938 Clinical Trial.

8

Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.

Pontiroli AE, Lanzi R, Monzani M, Musatti L, Guglielmone C, Pozza G. Pontiroli AE, et al. Among authors: musatti l. J Endocrinol Invest. 1992 Feb;15(2):85-91. doi: 10.1007/BF03348669. J Endocrinol Invest. 1992. PMID: 1569294 Clinical Trial.

9

Inhibition of lipolysis by nicotinic acid and by acipimox.

Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, Sirtori CR. Fuccella LM, et al. Among authors: musatti l. Clin Pharmacol Ther. 1980 Dec;28(6):790-5. doi: 10.1038/clpt.1980.236. Clin Pharmacol Ther. 1980. PMID: 7438693

10

Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.

Sirtori CR, Gianfranceschi G, Sirtori M, Bernini F, Descovich G, Montaguti U, Fuccella LM, Musatti L. Sirtori CR, et al. Among authors: musatti l. Atherosclerosis. 1981 Feb-Mar;38(3-4):267-71. doi: 10.1016/0021-9150(81)90042-3. Atherosclerosis. 1981. PMID: 7225165 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page